Introduction: Partner and localizer of BRCA2 (PALB2) is essential for homologous recombination repair. We examined mRNA levels of DNA repair genes, including partner and localizer of BRCA2 gene (PALB2), ring finger protein 8 gene (RNF8), replication timing regulatory factor 1 gene (RIF1), ATM serine/threonine kinase gene (ATM), and tumor protein p53 binding protein 1 gene (53BP1) as predictive biomarkers for cisplatin-docetaxel in the European phase III BRCA1, DNA repair associated (BRCA1)-receptor-associated protein 80 (RAP80) expression customization (BREC) phase III clinical trial (ClinicalTrials.gov identifier NCT00617656).
of response to cisplatin-docetaxel. Specifically, an objective response rate of 77% to cisplatin-docetaxel was observed for patients with high PALB2 mRNA expression compared with a rate of only 23 % for those with low PALB2 mRNA expression (p ¼ 0.0448).
Conclusions: High PALB2 mRNA expression identified patients with NSCLC who significantly benefited from cisplatin-docetaxel chemotherapy in the European BREC phase III clinical trial. The combination of chemotherapy with immunotherapy will become the standard of care, and a predictive marker of response to chemotherapy may accurately guide therapeutic decision making.
Introduction
Pharmacogenomic strategies for customizing chemotherapy in NSCLC are not recommended for treatment selection. We linked BRCA1, DNA repair associated (BRCA1) and its upstream partner, receptor-associated protein 80 (RAP80 [an alias for UIMC1]), to platinum resistance and sensitivity to antimicrotubule drugs. 1 RAP80 is required for BRCA1 accumulation to DNA break sites. 2 The BRCA1-RAP80 expression customization (BREC) studies were two industry-independent biomarkerdirected trials in European (Spanish Lung Cancer Group in collaboration with the French Lung Cancer Group) and Chinese patients with advanced-stage NSCLC. 3 In the phase III European study, patients randomized to the control arm (cisplatin-docetaxel) had significantly better median overall survival (OS) than did those who received customized chemotherapy based on levels of BRAC1 and receptorassociated protein 80 gene (RAP80 [an alias for UIMC1]) mRNA. Accrual of the study was closed prematurely. 3 The BREC studies failed to show benefit from the BRCA1/RAP80 pharmacogenetic approach. However, other factors can influence the predictive significance of BRCA1/RAP80. 4 In RAP80-depleted cells, tumor protein p53 binding protein 1 (53BP1 [an alias of TP53BP1]) and RAD51 recombinase (RAD51) assemble at doublestrand breaks, whereas in BRCA1-depleted cells, RAP80 and 53BP1 take on this role. 5 Replication timing regulatory factor 1 (RIF1 [also known as Rap1 interacting factor 1]) is the main factor downstream of 53BP1 in the control of 5' end resection (Fig. 1) . Its function is dependent on the ATM serine/threonine kinase gene (ATM). 6, 7 Low BRCA1 and high 53BP1-RIF1 could be a better combination to predict resistance to platinum-based chemotherapy. The inhibition of E3 ubiquitinprotein ligase RING finger protein 8 (RNF8) suppresses BRCA1 independent of homologous recombination in 53BP1-depleted cells and RNF8 connects homologous recombination and nonhomologous end joining. 5 Finally, partner and localizer of BRCA2 (PALB2) is required for BRCA2, DNA repair associated (BRCA2) localization in DNA damage sites 8 (see Fig. 1 ). Any defect in the BRCA1-PALB2-BRCA2-RAD51 complex can result in defective assembly of RAD51 foci and could be predictive of response to DNA interstrand cross-linking agents. Because BRCA1 regulates endogenous microtubule dynamics and its loss confers resistance to taxanes, 9 the BRCA1-PALB2-BRCA2 network may be a critical determinant of the responsiveness to antimicrotubule agents.
A prespecified secondary objective of the BREC clinical trial was the study of potential genetic markers of response or resistance to chemotherapy. In the present study, we have investigated the association between mRNA expression of partner and localizer of BRCA2 gene (PALB2), ring finger protein 8 gene (RNF8), replication timing regulatory factor 1 gene (RIF1), ATM, and tumor protein p53 binding protein 1 gene (53BP1 [an alias of TP53BP1]) and outcome to cisplatin-docetaxel in European patients with NSCLC in the control arm and group 2 of the experimental arm of the BREC study.
Methods
The present study includes all European patients with NSCLC who were treated with cisplatin-docetaxel in the BREC trial 3 and had sufficient stored tumor material. RNA was extracted from formalin-fixed paraffin-embedded tissue samples, and mRNA expression of PALB2, RNF8, RIF1, ATM, and 53BP1 was evaluated by quantitative real-time polymerase chain reaction, as previously described. 10 Gene expression levels were grouped on the basis of tertiles (Q33, Q66) and divided as high (>Q66 and Q33-Q66) or low (<Q33). The primary end point of the study was to examine the effects of gene mRNA expression levels on survival and responses. Further details are provided in the Supplementary Material. The BREC study is registered under ClinicalTrials.gov identifier NCT00617656.
Results
A total of 191 patients with NSCLC were treated with cisplatin-docetaxel (142 in the control group and 49 in group 2) in the European BREC phase III study. 3 Among them, 177 had material left for further molecular analysis. The baseline characteristics of the patients are shown in Supplementary  Table 1 .
Among the five biomarkers explored, PALB2 and RIF1 were significantly associated with progressionfree survival (PFS). At the time of the interim analysis of the BREC study, 3 patients with high PALB2 mRNA expression had a median PFS of 5.6 months, compared with 4.1 months for those with low PALB2 mRNA expression (hazard ratio [HR] ¼ 0.56, 95% confidence interval [CI]: 0.38-0.80, p ¼ 0.0020) ( Fig. 2A) . In patients with high and low RIF1 mRNA expression, the median PFS times were 5.9 and 3.9 months, respectively (HR ¼ 0.60, 95% CI: 0.42-0.87, p ¼ 0.0069). In the univariate analysis for PFS, PALB2 and RIF1 emerged as significant factors for better PFS when highly expressed (Fig. 2B) . In the multivariate analysis, only PALB2 remained a significant biomarker to affect PFS (HR ¼ 0.63, 95% CI: 0.42-0.83, p ¼ 0.0018). The Cox regression model included Eastern Cooperative Oncology Group performance status, sex, age, and histologic type as additional exploratory variables.
PALB2 was found to be significantly associated with OS. Patients with high PALB2 mRNA expression had a median OS of 13.2 months compared with 9.9 months for those with low PALB2 mRNA expression (HR ¼ 0.64, 95% CI: 0.42-0.97, p ¼ 0.0394) (Fig. 3A) . The univariate analysis established the clinical importance of PALB2 mRNA expression for OS (HR ¼ 0.63, 95% CI: 0.42-0.83, p ¼ 0.0080) (Fig. 3B) . In a multivariate Cox regression model that was built with PALB2, RIF1, Eastern Cooperative Oncology Group performance status, sex, age, and histologic type as exploratory variables, PALB2 mRNA expression emerged as the only significant factor to affect OS (HR ¼ 0.68, 95% CI: 0.42-0.90, p ¼ 0.0104).
Concerning response to treatment, among the 158 patients evaluable for response, cisplatin-docetaxel induced an objective response rate (ORR) of 77% in patients with high PALB2 mRNA expression compared with 23% in those with low PALB2 mRNA expression (p ¼ 0.0448). RIF1 was also significantly correlated with ORR. ORR was significantly higher in patients with high RIF1 mRNA expression (79%) than in patients with low RIF1 mRNA expression (21%) (p ¼ 0.0018).
Finally, using MTT viability (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays, we determined the influence of PALB2 gene silencing on NSCLC cell viability. We observed that after lentivirus infection, the cell proliferation rate of the docetaxeltreated PALB2 knockdown group was increased in both EBC1 and H1993 cells compared with the rate in the docetaxel-treated control group, (Fig. 4) .
Discussion
PALB2 is recognized as an essential gene of susceptibility to breast and pancreatic cancer. PALB2 loss-offunction mutations are associated with sensitivity to DNA-damaging agents and poly(ADP-ribose) polymerase 1 inhibitors. 11 To the best of our knowledge, this is the first study to explore PALB2 mRNA expression as a predictive pharmacogenomic marker in NSCLC. We found that PALB2, when highly expressed, is predictive of outcome in response to cisplatin-docetaxel. Among the five DNA repair genes explored, RIF1 was also significantly related to PFS and response to cisplatin-docetaxel, but unlike PALB2, it did not remain significant in the PFS Cox regression model. PALB2 has functions that are different from those of its main interactors, BRCA1 and BRCA2, including its synergism with p53 to suppress breast tumor formation. 12 Constitutive activation of nuclear factor kappa light-chain enhancer of activated B cells was found in PALB2-mutant mice after exposure to radiation. 13 Although higher p53 induction was observed after radiation, there were lower apoptosis levels than in wildtype mice, highlighting a prosurvival and prooncogenic role of nuclear factor kappa light-chain enhancer of activated B cells in PALB2-mutant mice. 13 On the other hand, PALB2 interacts with Kelch-like ECH-associated protein 1 (KEAP1), a negative regulator of the antioxidant transcription factor nuclear factor erythroid 2-like 2 (NFE2L2 [also known by the alias NRF2]). Therefore, PALB2 promotes NRF2 nuclear accumulation and function. In NSCLC, high levels of NRF2 protein are associated with poor outcome and resistance to therapy. Higher PALB2 mRNA expression has been associated with poorer OS in patients with advanced breast cancer. 16 In The Cancer Genome Atlas RNA-seq database no significant prognostic significance is reported for PALB2 mRNA expression in patients with lung adenocarcinoma or lung squamous cell carcinoma. 17 Overall, in the BREC study, the BRCA1/RAP80 model was not able to customize chemotherapy for patients with NSCLC. 3 In non-oncogene-addicted NSCLC, the combination of platinum-based chemotherapy with immunotherapy is emerging as a promising therapeutic approach. 18 Therefore, PALB2 mRNA expression as a predictor of outcome in response to platinum-based chemotherapy warrants further investigation.
The findings of this prespecified secondary analysis of the BREC clinical trial are interesting. Caution should be taken, however, considering that the cutoff points for defining high and low mRNA expression were derived internally from this data set. Although tissue was available for 92% of the cisplatin-docetaxeltreated patients and PALB2 mRNA expression was successfully evaluated in almost 90% of them, the 45 cisplatin-gemcitabine-treated patients of experimental group 1 and the 43 patients of experimental group 3 who were treated with docetaxel alone were not included in this analysis.
This study suggests that high PALB2 mRNA expression is related to a better outcome in response to cisplatin-docetaxel in advanced patients with NSCLC. Revalidation of the findings and refinements of the mRNA expression cutoff points are required before clinical application. Nowadays, because combinations of chemotherapy with immunotherapy will become the standard of care, an enrichment strategy with a chemotherapy-related biomarker may increase the clinical benefit of such approaches.
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